Glossary

An asset evaluation establishes the attractiveness, market potential and likelihood of success for an internal or external asset.

Bibliometric analysis is the application of statistical methods to the study of publication data.

Clinical development is the systematic process of testing a new medical intervention in humans to establish its safety and efficacy.

Clinical landscaping is a comprehensive assessment that provides a holistic view of a particular therapeutic area.

Competitive landscaping is the analysis of current and future market competitors to inform strategic business decisions.

A development pipeline is a set of drug candidates that an individual pharmaceutical company (or the entire industry collectively) has under discovery or development at any given point in time.

A DOL is an influential person or organization with a large online presence, often on social media, in the healthcare or pharmaceutical industry.

Epidemiology is the study of the distribution, patterns and determinants of health across defined populations.

A health technology assessment (HTA) is a systematic evaluation of the clinical, social, economic and ethical implications of a new medical intervention or technology.

In epidemiology, incidence is the rate at which new cases of a disease occur in a population over a specific time period.

Indications are the specific medical conditions or diseases for which a treatment or intervention is approved.

Journal scoping is a strategic process used to identify the most suitable academic journal for publishing research.

A Key Clinical Investigator (KCI) is a highly experienced healthcare professional with a proven track record in conducting successful clinical trials.

A Key Opinion Leader (KOL) is a highly influential and respected expert in their field who shapes opinions and decisioning.

Launch sequence optimization is a strategic process that determines the best order and timing for launching a new drug across different markets.

Market Access is a function within pharmaceutical and biotechnology companies ensuring that the patients most likely to benefit from a new drug can access it, and that the drug is both cost-effective for healthcare systems and commercially viable for the manufacturer.

Medical Affairs is a strategic function within the pharmaceutical, biotechnology and consumer healthcare industries that communicates scientific data to healthcare professionals, payers and policymakers.

A Payer Influencing Key Opinion Leader (PIKOL) is a key influencer of healthcare policy and reimbursement decisions.

In epidemiology, prevalence describes the proportion of a population that has a disease at a specific point in time.

Product value communication is the strategic process of articulating the unique attributes, patient benefits, and economic value of a drug or therapy.

A Rising Star is a medical or scientific professional in the early to mid-stage of their career who demonstrates potential to become a prominent and influential voice in their field.

Stakeholder mapping is the creation of a comprehensive overview of key stakeholders relevant to a particular therapeutic area, indication, condition or product.

Trial site analysis is the evaluation of potential clinical trial sites to optimize study performance.